FARUK ÇİÇEKCİ
(Selçuk University, Medical Faculty, Anesthesiology and Reanimasion, Konya, Turkey)
Dincer YUKSEKKAVAS
(Konya E Type Prison, Department of Medicine, Konya, Turkey)
ADEM AYDIN
(Necmettin Erbakan University)
ADNAN KARAİBRAHİMOĞLU
(Necmettin Erbakan University, Medical Faculty, Department of Medical Education and Informatics, Konya, Turkey)
ALİ ULVİ UCA
(Necmettin Erbakan University)
Yıl: 2017Cilt: 34Sayı: 3ISSN: 1300-1817 / 1302-1664Sayfa Aralığı: 242 - 251İngilizce

137 2
The Comparison of Socio-Demographic and Clinical Variables of Inmates Using Gabapentin For Medicinal Purposes and Those Abusing The Drug
Amaç: Gabapentini tedavi amaçlı-endikasyonlu kullanan mahkumlar ile kötüye kullanan mahkumlar arasındaki sosyodemoğrafik ve klinik verileri karşılaştırmak. Metod: Bu çalışmaya Haziran 2012-Aralık 2014 yılları arasında Konya E Tipi Cezaevinde kalan, cezaevi polikliniğine başvuran ve ağrı polikiliniğimize sevkedilen gabapentin kullananlar mahkumlar dahil edildi. Gabapentini mevcut şikayetlerinden dolayı endikasyonsuz kullananlar (Grup 1), hastalığa bağlı olarak endikasyonlu kullananlar (Grup 2) DSM IV-TR `ye göre madde bağımlılığı, madde kötüye kullanımı ve gabapentin kötüye kullanımı yönünden araştırıldı. Bulgular: Endikasyonsuz gabapentin kullanan mahkumların (Grup 1) tamamına yakını (n:21) gabapentini kas ağrıları, nöropatik ağrı, uyku bozukluğu, anksiyete belirtileri, terleme, titreme ve bulantı-kusma için kullandığını belirtirken, endikasyonlu olarak gabapentini kullanan mahkumlar (Grup 2) daha çok mevcut hastalıklarının belirtilerini baskılamak için (diyabetik nöropati, ve epilepsi) kullandıkları tespit edilmiştir. Endikasyonsuz kullanan grubun birinci derece yakınlarında alkol/madde kullanımının daha yüksek olduğu belirlenmiştir (P<0.001). Grup 1 için madde bağımlılığı (n=10) ve madde kötüye kullanımı (n=13) anlamlı olarak Grup 2´den yüksek bulunmuştur (P<0.001). Sonuç: DSM IV-TR`ye göre madde bağımlılığı ve madde kötüye kullanımı tanısı alan mahkumların cezaevine girdikten sonra özellikle opioid çekilme belirtilerini engellemek için gabapentin kullandıkları ve gabapentin kötüye kullanımı tanımına uydukları görülmüştür
Fen > Tıp > Nörolojik Bilimler
DergiAraştırma MakalesiErişime Açık
  • 1. Johanson CE, Balster RL, Henningfield JE, et al. Risk management and post-marketing surveillance fort he abuse of medications acting on the central nervous system: expert panel report. Drug Alcohol Depend 2009;105(Suppl.1):65-71.
  • 2. Del Paggio D. Psychotropic medication abuse in correctional facilities. Bay Area Psychopharmacology Newsletter 2005;8:1-5.
  • 3. Markowitz JS, Finkenbine R, Myrick H, King L, Carson WM. Gabapentin abuse in a cocain user: implications for treatment? Clin Psychopharmacol 1997;17:423-424.
  • 4. Reccoppa L, Malcolm R., Ware M. Gabapentin abuse in inmates with prior history of cocaine dependence. The American Juournal on Addictions 2004;13:321-323.
  • 5. Pittenger C, Desan PH. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. J Clin Psychiatry 2007;68:483-484.
  • 6. Magnus L. Nonepileptic uses of gabapentin. Epilepsia 1999;40 (Suppl 6):566-572
  • 7. Palmer CM, Pope HG Jr. Antiepileptic drugs. In: Gelder MG, Lopez-Ibor JJ, A nderson N, editors. New Textbook of Psychiatry. Vol. 2, 1st ed. New York: Oxford University Press, 2000;1326-1333.
  • 8. British National Formulary, 2014. Gabapentin. http://www.medicinescomplete.com/mc/bnf/current/ PHP2930-gabapentin.htm q=gabapentin&t=search&ss=text&p=1#_hit (Accessed 1 Apr 2014).
  • 9. Canadian Agency for Drug and Technologies in Health (CADTH). Abuse and misuse potential of pregabalin: a reviwe of the clinical evidence; Contex and policy issues; 2012
  • http://dpic.org/sites/default/files/Pregabalin/Abuse_ CADTH_24Apr2012.pdf (Accessed 20 Feb 2014)
  • 10. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropatic pain: a systematic review of controlled and uncontrolled literature. Clin J Pain 2001;17:284-295.
  • 11. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57:451-462.
  • 12. Anton RF, Myric H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptomps. J Clin Psychopharmacol 2009;29:334-342.
  • 13. Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 1999a;32:107-109.
  • 14. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind,placebo-controlled trial. J Clin Psychiatry 2007;68:1691-1700.
  • 15. Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Phychiatry 2001;62:19-23.
  • 16. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83:4-7.
  • 17. McCabe SE, Boyd CJ, Teter CJ. Subtypes of nonmedical prescription drug misuse. Drug Alcohol Depend 2009;102:63-70.
  • 18. Pumariega AJ, Burakgazi H, Unlu A, Prajapati P, Dalkilic A. Substance Abuse: Risk Factors for Turkish Youth. Bulletin of Clinical Psychopharmacology 2014;24:5-14.
  • 19. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. Randomized doubleblind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008;32:1429-1438.
  • 20. Finnerup NB, Sindrup, SH, Jensen TS. The evidence for pharmacological treatment of neuropatic pain. Pain 2010;150:573-581.
  • 21. Freye E, Levy JV, Partecke L. Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD) correlation with neurophysiological parameters. Neurophysiol Clin 2004;34:81-89.
  • 22. Howland RH. Gabapentin for treatment of substance use disorders. Journal of Psychosocial Nursing and Mental Health Services 2013;5111- 5114.
  • 23. Martinez-Raga J, Sabater A, Perez-Galvez B, Castellano M, C Ervera G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psyhiatry 2004;28:599-601.
  • 24. McLean RJ, Gottlob I. The pharmcological treatment of nystagmus: a review. Expert Opinion on pharmacotherapy 2009;10:1805-1816.
  • 25. Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause. A systemic reviewand meta-analysis. Clinical Therapeutics 2009;31:221-235.
  • 26. Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today (Barc) 2004;40:603-619.
  • 27. Karam-Hage M, Brower KJ. Gabapentin treatment for insomia associated with alcohol dependence(letter). Am J Psychiatry 2000;157-151.
  • 28. Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insomia in alcoholic patients. Psychiatry Clin Neurosci 2003;57:542-544.
  • 29. Pollack MH, Mattheews J,Scott EL. Gabapentin as a potantial treatment for anxiety disorders. Am J Psychiatry 1998;155:992-993.
  • 30. Gironell A1 , Kulisevsky J, Barbanoj M, LópezVillegas D, Hernández G, Pascual-Sedano B. A randomized placebo controlled comparative trial of gabapentin and propranolol in essantial tremor. Arch Neurol 1999;56:475-480.
  • 31. Ondo WG. Essential tremor: treatment options. Curr Treat Options Neurol 2006;8: 256-267.
  • 32. Bonnet U, Banger M, Leweke FM, Specka M, Muller BW, Hashemi T. Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Psychopharmacol 2003b;23:514-519.
  • 33. Kumar P, Jain MK. Gabapentin in the management of pentazocine dependency: a potent analgesic anticraving agent. J Assoc Physicians India 2003;51:673-6.
  • 34. Raby WN, Coomaraswamy S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry 2004; 65: 84-86.
  • 35. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005; Issue 3, Art no:CD005452.
  • 36. Arnold LM, Goldenberg DL, Stanford SB, et al,. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336- 1344.
  • 37. Sullivan GM, Coplan JD. Anxietry disorders: biochemical aspects. In: Sadock BJ, Sadock VA, editors. Comprehensive Textbook of Psychiatry Vol.1. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2000:1450-1456.
  • 38. Chouinard G, Beauclair L, Belanger MC. Gabapentin: long term antianxiety and hypnotic effects in psychiatric patient with comorbit anxiety related disorders. Can J Psychiatry 1998;43:305.
  • 39. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348.
  • 40. Pande AC, Pollack MH, Crockatt MA, et al. Placebo-controlled study of gabapentin teatment of panic disorder. J Clin Psychopharmacol 2000;20:467-471.
  • 41. Singh L, Field M, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive action that are reversed by Dserine. Psychopharmacology (Berl) 1996;127:1-9.
  • 42. Schlicker E, Reimann W, Gothert M, Kratzschmar S. Gabapentin decreases monoamine relase without affecting acetylcholine release in the brain. Arzneimittelfirsschung 1985;35:1347-1349.
  • 43. Dougherty JA, Rhoney DH. Gabapentin: A unique anti-epileptic agent. Neurol Res 2001;23:821-9.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.